Kura Oncology ROA 2024

Ce face Kura Oncology?

Kura Oncology Inc. is a biopharmaceutical company specializing in the development of innovative cancer therapies. Founded in 2014, the company aims to meet the needs of patients with rare cancer types. The story of Kura Oncology began with a focus on the treatment of leukemia and lymphoma, but through intensive research and development, the company has expanded its presence to other cancer types, such as colon and lung cancer. The company uses a platform that focuses on the discovery and development of molecules targeting specific cancer types. This platform is based on extensive databases derived from a deep understanding of cancer biology, clinical experience, and state-of-the-art technology. Kura Oncology's business model is based on the development of treatment methods targeting the specific needs of patients with rare cancer diseases. The goal is to develop therapies that can more effectively combat these types of cancers than conventional treatment methods. The company has several areas of focus. The largest area is the discovery and development of drugs. Kura Oncology has identified a variety of molecules targeting specific types of cancer and is further developing them in clinical studies. Among the products offered by Kura Oncology is a collection of drug candidates. This includes Tipifarnib, which targets the focus of farnesyltransferase, an enzyme overexpressed in some types of cancer, as well as KO-947, which blocks the activity of SHP2 inhibitor, an enzyme that suppresses overactive signaling pathways that promote tumor progression. The company also engages in partnerships to maximize the potential of its research platform. For example, Kura Oncology has established a collaboration with Janssen Pharmaceuticals Inc., a wholly-owned subsidiary of Johnson & Johnson, with the aim of exchanging drug candidates. It also conducts clinical studies to demonstrate the efficacy and safety of its drug candidates. Recently, the company has made notable progress. For example, it obtained approval for a clinical study for its treatment of certain types of tumors in 2018. Kura Oncology has since relocated its headquarters to San Diego, California, and employs over 100 employees. The company has also built a strong network of academic partners, clinicians, and investors to support its mission. The company is constantly striving to expand its portfolio and develop innovative solutions for cancer treatment. Kura Oncology has made a name for itself in clinical research and is working hard to find new and improved therapies that can improve the lives of patients living with rare cancer types. Kura Oncology ist eines der beliebtesten Unternehmen auf Eulerpool.com.